BRIEF-Conduent Announces Agreement To Sell Its Casualty Claims Solutions Business To Medrisk-June 2024-www.financetom.com

BRIEF-Conduent Announces Agreement To Sell Its Casualty Claims Solutions Business To Medrisk

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Conduent Announces Agreement To Sell Its Casualty Claims Solutions Business To Medrisk

May 3, 2024 6:41 AM

May 3 (Reuters) - Conduent Inc ( CNDT ):

* CONDUENT ANNOUNCES AGREEMENT TO SELL ITS CASUALTY CLAIMS

SOLUTIONS BUSINESS TO MEDRISK

* CONDUENT INC ( CNDT ): SALE, FOR $240 MILLION IN CASH

* CONDUENT INC ( CNDT ) - AS PART OF THIS TRANSACTION, CURRENT

CONDUENT

EMPLOYEES IN CASUALTY CLAIMS SOLUTIONS BUSINESS WILL JOIN

MEDRISK

* CONDUENT INC ( CNDT ) - CONDUENT WILL CONTINUE TO PROVIDE MAILROOM

SERVICES FOR CURRENT CASUALTY CLAIMS CLIENTS INCLUDING MEDRISK

Source text for Eikon:

Further company coverage:

Previous page： Nutrien Ratings Affirmed by S&P; Business Risk Profile Revised To Strong Next page： Why Avidity Biosciences Shares Are Trading Higher Wednesday

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Nutrien Ratings Affirmed by S&P; Business Risk Profile Revised To Strong

Jun 12, 2024

11:07 AM EDT, 06/12/2024 (MT Newswires) -- S&P Global Ratings on Wednesday affirmed its BBB long-term issuer credit rating on Nutrien ( NTR ) on a resilient operating model. The rating agency also affirmed the BBB issue-level rating on the Canadian fertilizer company's unsecured debt and the short-term A-2 global scale and global scale commercial paper ratings on Nutrien (...

Why Avidity Biosciences Shares Are Trading Higher Wednesday

Jun 12, 2024

Avidity Biosciences ( RNA ) stock is moving higher Wednesday following the company’s announcement that the Phase 1/2 FORTITUDE trial yielded positive results. The Details: The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran. Data from the trial showed functional improvements across patients with the disease, greater than 50% mean reductions in DUX4...

--Johnson Controls International Keeps Quarterly Dividend at $0.37 a Share, Payable July 19 to Shareholders of Record June 24

Jun 12, 2024

11:15 AM EDT, 06/12/2024 (MT Newswires) -- Price: 70.84, Change: +0.29, Percent Change: +0.41 ...

Amazon Gets Injunction Vacated by Appeals Court in Unfair Labor Practice Case

Jun 12, 2024

11:15 AM EDT, 06/12/2024 (MT Newswires) -- The US Court of Appeals for the Second Circuit on Wednesday vacated an injunction against Amazon.com ( AMZN ) granted by a district judge that determined there was reasonable cause to believe the company committed an unfair labor practice by firing an employee engaged in protected concerted activity. The injunction was seeking, among...